Farringdon Capital, Ltd. Repligen Corp Transaction History
Farringdon Capital, Ltd.
- $198 Billion
- Q1 2025
A detailed history of Farringdon Capital, Ltd. transactions in Repligen Corp stock. As of the latest transaction made, Farringdon Capital, Ltd. holds 2,506 shares of RGEN stock, worth $309,115. This represents 0.16% of its overall portfolio holdings.
Number of Shares
2,506
Previous 1,558
60.85%
Holding current value
$309,115
Previous $224 Million
42.19%
% of portfolio
0.16%
Previous 0.09%
Shares
2 transactions
Others Institutions Holding RGEN
# of Institutions
495Shares Held
57.6MCall Options Held
75.6KPut Options Held
521K-
Black Rock Inc. New York, NY7.57MShares$934 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD7.57MShares$933 Million0.12% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.08MShares$627 Million0.01% of portfolio
-
State Street Corp Boston, MA1.69MShares$208 Million0.01% of portfolio
-
Invesco Ltd. Atlanta, GA1.67MShares$207 Million0.04% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $6.84B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....